...
首页> 外文期刊>Antiviral Research >Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir
【24h】

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir

机译:通过三重组合抗腺病毒siRNA,可溶性腺病毒受体陷阱sCAR-Fc和西多福韦来增强对腺病毒复制的抑制

获取原文
获取原文并翻译 | 示例
           

摘要

Adenoviruses (Ad) generally induce mild self-limiting respiratory or intestinal infections but can also cause serious disease with fatal outcomes in immunosuppressed patients. Antiviral drug therapy is an important treatment for adenoviral infections but its efficiency is limited. Recently, we have shown that gene silencing by RNA interference (RNAi) is a promising new approach to inhibit adenoviral infection. In the present in vitro study, we examined whether the efficiency of an RNAi-based anti-adenoviral therapy can be further increased by combination with a virus receptor trap sCAR-Fc and with the antiviral drug cidofovir. Initially, three siRNAs, siE1A_4, siIVa2_2 and Pol-si2, targeting the adenoviral E1A, IVa2 and DNA polymerase mRNAs, respectively, were used for gene silencing. Replication of the Ad was inhibited in a dose dependent manner by each siRNA, but the efficiency of inhibition differed (Pol-si2 > siIVa2_2 > siE1A_4). Double or triple combinations of the siRNAs compared with single siRNAs did not result in a measurably higher suppression of Ad replication. Combination of the siRNAs (alone or mixes of two or three siRNAs) with sCAR-Fc markedly increased the suppression of adenoviral replication compared to the same siRNA treatment without sCAR-Fc. Moreover, the triple combination of a mix of all three siRNAs, sCAR-Fc and cidofovir was about 23-fold more efficient than the combination of siRNAs mix/sCAR-Fc and about 95-fold more efficient than the siRNA mix alone. These data demonstrate that co-treatment of cells with sCAR-Fc and cidofovir is suitable to increase the efficiency of anti-adenoviral siRNAs. (C) 2015 Elsevier B.V. All rights reserved.
机译:腺病毒(Ad)通常会引起轻度的自限性呼吸道或肠道感染,但也会在免疫抑制患者中引起严重的疾病,并具有致命的后果。抗病毒药物疗法是治疗腺病毒感染的重要方法,但其效果有限。最近,我们已经表明,通过RNA干扰(RNAi)沉默基因是抑制腺病毒感染的一种有前途的新方法。在目前的体外研究中,我们研究了通过与病毒受体陷阱sCAR-Fc和抗病毒药物西多福韦联合使用,是否可以进一步提高基于RNAi的抗腺病毒治疗的效率。最初,分别针对腺病毒E1A,IVa2和DNA聚合酶mRNA的三个siRNA,siE1A_4,siIVa2_2和Pol-si2用于基因沉默。每个siRNA均以剂量依赖性方式抑制Ad的复制,但抑制效率有所不同(Pol-si2> siIVa2_2> siE1A_4)。与单个siRNA相比,siRNA的双重或三重结合不会导致对Ad复制的明显抑制。与没有sCAR-Fc的相同siRNA处理相比,将siRNA(单独或两种或三种siRNA或两种或三种的混合物)与sCAR-Fc的结合显着提高了对腺病毒复制的抑制。而且,所有三种siRNA,sCAR-Fc和西多福韦的混合物的三重组合比siRNA混合物/ sCAR-Fc的组合高约23倍,比单独的siRNA混合物高约95倍。这些数据表明,用sCAR-Fc和西多福韦共同处理细胞适合提高抗腺病毒siRNA的效率。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号